000148789 001__ 148789
000148789 005__ 20240229123034.0
000148789 0247_ $$2doi$$a10.1038/s41568-019-0223-8
000148789 0247_ $$2pmid$$apmid:31819232
000148789 0247_ $$2ISSN$$a1474-175X
000148789 0247_ $$2ISSN$$a1474-1768
000148789 0247_ $$2altmetric$$aaltmetric:72447409
000148789 037__ $$aDKFZ-2019-03302
000148789 041__ $$aeng
000148789 082__ $$a610
000148789 1001_ $$aHovestadt, Volker$$b0
000148789 245__ $$aMedulloblastomics revisited: biological and clinical insights from thousands of patients.
000148789 260__ $$aLondon [u.a.]$$bNature Publ. Group$$c2020
000148789 3367_ $$2DRIVER$$aarticle
000148789 3367_ $$2DataCite$$aOutput Types/Journal article
000148789 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1580111018_3899$$xReview Article
000148789 3367_ $$2BibTeX$$aARTICLE
000148789 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000148789 3367_ $$00$$2EndNote$$aJournal Article
000148789 520__ $$aMedulloblastoma, a malignant brain tumour primarily diagnosed during childhood, has recently been the focus of intensive molecular profiling efforts, profoundly advancing our understanding of biologically and clinically heterogeneous disease subgroups. Genomic, epigenomic, transcriptomic and proteomic landscapes have now been mapped for an unprecedented number of bulk samples from patients with medulloblastoma and, more recently, for single medulloblastoma cells. These efforts have provided pivotal new insights into the diverse molecular mechanisms presumed to drive tumour initiation, maintenance and recurrence across individual subgroups and subtypes. Translational opportunities stemming from this knowledge are continuing to evolve, providing a framework for improved diagnostic and therapeutic interventions. In this Review, we summarize recent advances derived from this continued molecular characterization of medulloblastoma and contextualize this progress towards the deployment of more effective, molecularly informed treatments for affected patients.
000148789 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000148789 588__ $$aDataset connected to CrossRef, PubMed,
000148789 7001_ $$00000-0002-7942-6674$$aAyrault, Olivier$$b1
000148789 7001_ $$00000-0002-8460-4367$$aSwartling, Fredrik J$$b2
000148789 7001_ $$00000-0001-7441-9486$$aRobinson, Giles W$$b3
000148789 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b4$$udkfz
000148789 7001_ $$00000-0002-1220-5252$$aNorthcott, Paul A$$b5
000148789 773__ $$0PERI:(DE-600)2060549-3$$a10.1038/s41568-019-0223-8$$gVol. 20, no. 1, p. 42 - 56$$n1$$p42 - 56$$tNature reviews / Cancer Cancer [...]$$v20$$x1474-1768$$y2020
000148789 909CO $$ooai:inrepo02.dkfz.de:148789$$pVDB
000148789 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000148789 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000148789 9141_ $$y2020
000148789 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000148789 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000148789 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000148789 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT REV CANCER : 2017
000148789 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000148789 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000148789 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000148789 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000148789 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000148789 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000148789 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000148789 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000148789 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000148789 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000148789 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings
000148789 915__ $$0StatID:(DE-HGF)9940$$2StatID$$aIF >= 40$$bNAT REV CANCER : 2017
000148789 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000148789 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000148789 980__ $$ajournal
000148789 980__ $$aVDB
000148789 980__ $$aI:(DE-He78)B062-20160331
000148789 980__ $$aI:(DE-He78)HD01-20160331
000148789 980__ $$aUNRESTRICTED